Interview with InSightec President and CEO, Kobi Vortman

InSightec reports that two new sites have joined its Phase 1 clinical trial assessing the ExAblate Prostate System and 14 patients with low-risk prostate cancer have now received treatment.
The newly added sites are the University of Rome in La Sapienza, Italy and Jaslok Hospital in Mumbai, India. The other participating sites are the N.N. Petrov Research Institute of Oncology in Saint Petersburg, Russia and the National Cancer Centre at the Singapore General Hospital in Singapore.

Category:

Science & Technology

Tags:

• Kobi Vortman
• Insightec
• Exablate
• clinical trial
• prostate
• cancer
• treatment
• University of Rome
• Jaslok Hispital
• N.N. Petrov Research Institute
• National Cancer Center
• Singapore
• Russia
• India
• Italy
• Focused Ultrasound